Company intelligence / Profile preview

Artemis Growth Partners

London, England, United Kingdomartemisgrowth.com ↗

Ownership: Private
Development stage: Commercial

Overview

Artemis Growth Partners manages over $400 million in assets across five equity funds and one debt fund. It invests globally in the legal cannabis value chain—including branded products, distributors, ancillary services, and science-driven R&D platforms—with a focus on ESG/impact investing. Its portfolio includes 39 companies spanning North/South America and Europe. The company does not conduct clinical trials itself but invests in firms that may be at various stages of product development or commercialization.

Therapeutic areas: OtherPsychiatryNeurology
Modalities: Plant-derived cannabinoidsCannabis-based therapeutics/productsPlatform/Marketplace
Industry: Investors

Partnerships

Leaf Trade (now part of LeafLink)Bloomwell GroupJane TechnologiesConception NurseriesMedcolcanna

Beyond the preview

Go deeper on Artemis Growth Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artemis Growth Partners.

Explore the full profile